{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:18Z","timestamp":1791478218767,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.vaccine.2012.08.021","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T20:30:21Z","timestamp":1345667421000},"page":"6409-6415","source":"Crossref","is-referenced-by-count":60,"title":["Relative stability of meningococcal serogroup A and X polysaccharides"],"prefix":"10.1016","volume":"30","author":[{"given":"F.","family":"Berti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Micoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cappelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gavini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pluschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.08.021_bib0005","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0010","unstructured":"http:\/\/www.who.int\/nuvi\/meningitis\/en\/index.html."},{"key":"10.1016\/j.vaccine.2012.08.021_bib0015","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.330.6010.1466","article-title":"Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks?","volume":"330","author":"Roberts","year":"2010","journal-title":"Science"},{"issue":"Suppl.","key":"10.1016\/j.vaccine.2012.08.021_bib0020","first-page":"1","volume":"28","author":"Lapeyssonnie","year":"1963","journal-title":"Bull World Health Organ"},{"issue":"5","key":"10.1016\/j.vaccine.2012.08.021_bib0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3855\/jidc.193","article-title":"Control of meningococcal meningitis outbreaks in sub-Saharan Africa","volume":"2","author":"Chippaux","year":"2008","journal-title":"J Infect Dev Ctries"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.08.021_bib0030","doi-asserted-by":"crossref","first-page":"B13","DOI":"10.1016\/j.vaccine.2009.04.062","article-title":"Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution","volume":"27","author":"LaForce","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0035","first-page":"499","article-title":"Epidemiology of bacterial meningitis in Niamey, Niger, 1981\u201396","volume":"77","author":"Campagne","year":"1999","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0040","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0045","first-page":"745","article-title":"Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines","volume":"81","author":"Robbins","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0050","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0021-9258(19)42828-7","article-title":"Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of Neisseria meningitidis serogroups A and X","volume":"249","author":"Bundle","year":"1974","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0055","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1003812","article-title":"Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans","volume":"364","author":"Sow","year":"2011","journal-title":"N Engl J Med"},{"issue":"1206","key":"10.1016\/j.vaccine.2012.08.021_bib0060","first-page":"29","article-title":"Menactra: a meningococcal conjugate vaccine","volume":"47","year":"2005","journal-title":"Med Lett Drugs Ther"},{"issue":"1343","key":"10.1016\/j.vaccine.2012.08.021_bib0065","first-page":"59","article-title":"A new conjugate meningococcal vaccine (Menveo)","volume":"52","year":"2010","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/846756","article-title":"Conjugate meningococcal vaccines development: gsk biologicals experience","volume":"846756","author":"Miller","year":"2011","journal-title":"Adv Prev Med"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0075","first-page":"603","article-title":"Peut-on individualiser deux nouveaux groupes s\u00e9rologiques de Neisseria meningitidis?","volume":"26","author":"Bories","year":"1966","journal-title":"Med Trop (Mars)"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0080","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/oxfordjournals.aje.a120854","article-title":"Prevalence of meningococcal serogroups and description of three new groups","volume":"87","author":"Evans","year":"1968","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3201\/eid0805.010227","article-title":"Clonal groupings in serogroup X Neisseria meningitidis","volume":"8","author":"Gagneux","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0090","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1046\/j.1469-0691.2003.00685.x","article-title":"Pascual A Infections by Neisseria meningitidis serogroup X in Spain","volume":"9","author":"del Castillo","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0095","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/00029330-200804010-00017","article-title":"A first meningococcal meningitis case caused by serogroup X Neisseria meningitidis strains in China","volume":"127","author":"Chen","year":"2008","journal-title":"Chin Med J"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0105","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1086\/339010","article-title":"Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana","volume":"185","author":"Gagneux","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.4269\/ajtmh.2009.80.619","article-title":"Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005\u20132006","volume":"80","author":"Mutonga","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0115","first-page":"227","article-title":"Epidemiological notes: meningococcal meningitis of serogroup X in Niamey (Niger)","volume":"50","author":"Etienne","year":"1990","journal-title":"Med Trop (Mars)"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0120","doi-asserted-by":"crossref","first-page":"e19513","DOI":"10.1371\/journal.pone.0019513","article-title":"Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso","volume":"6","author":"Delrieu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0125","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1016\/S0021-9258(19)42390-9","article-title":"Studies on the group-specific polysaccharide of Neisseria meningitidis serogroup X and an improved procedure for its isolation","volume":"249","author":"Bundle","year":"1974","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0130","first-page":"3578","article-title":"Enhanced stability of meningococcal polysaccharide vaccines by using lactose as a menstruum for lyophilization","volume":"55","author":"Tiesjema","year":"1977","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0135","unstructured":"Teodorovi\u0107 P. Synthesis of oligosaccharides related to the capsular polysaccharide of Neisseria meningitidis serotype A. Doctoral thesis. Stockholm University; 2005."},{"key":"10.1016\/j.vaccine.2012.08.021_bib0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1128\/IAI.37.1.89-103.1982","article-title":"Hydrolytic stability of pneumococcal group 6 (type 6A and 6B) capsular polysaccharides","volume":"37","author":"Zon","year":"1982","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0145","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1021\/ja00374a033","volume":"104","author":"Egan","year":"1982","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0150","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0264-410X(92)90091-W","article-title":"Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C","volume":"10","author":"Costantino","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0155","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.vaccine.2011.11.108","article-title":"Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi","volume":"30","author":"Micoli","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0160","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1016\/S0264-410X(99)00092-4","article-title":"Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines","volume":"17","author":"Ravenscroft","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0008-6215(96)00253-4","article-title":"Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production","volume":"296","author":"Lemercinier","year":"1996","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0170","unstructured":"Guidelines on stability evaluation of vaccines WHO\/BS\/06.2049; 2006."},{"key":"10.1016\/j.vaccine.2012.08.021_bib0175","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0180","unstructured":"Menveo\u00ae [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics Inc."},{"key":"10.1016\/j.vaccine.2012.08.021_bib0210","unstructured":"NimenrixTM: Summary of product characteristics.(http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002226\/WC500127663.pdf)."},{"key":"10.1016\/j.vaccine.2012.08.021_bib0190","unstructured":"March 30, 2007. Approval letter \u2013 Menactra\u00ae. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm131175.htm."},{"key":"10.1016\/j.vaccine.2012.08.021_bib0195","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein\u2013polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0200","first-page":"43","article-title":"Enhanced stability of meningococcal polysaccharide vaccines by using lactose as a menstruum for lyophilization","volume":"55","author":"Tiesjema","year":"1977","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2012.08.021_bib0205","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12012005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12012005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T04:39:34Z","timestamp":1643258374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12012005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":41,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0264410X12012005"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.08.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}